Christian Werno

This study introduces PEDRA, an ex vivo drug response assay that identifies patient-specific treatment options in metastatic biopsies, outperforming prior therapies and informing immune responses.

This study identifies MCSP+ melanoma cells as early metastasis founder cells in lymph nodes and shows they activate immunosuppression to evade CD8 T cell attack.

This study shows that inhibiting lysosomal acid lipase (LIPA) reduces breast cancer stemness and sensitizes triple-negative breast cancer (TNBC) cells to chemotherapy, suggesting LIPA as a novel therapeutic target.